With an upside potential of 99.1% and a relative strength index (RSI) of 33.8, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) ...

Recursion Pharmaceuticals (RXRX) has been drawing investor attention after recent trading shifts, with the stock closing at US$3.01 and showing mixed performance over the past week, month, and past ...

The opportunity is not in buying every low-priced penny stock but rather in finding smaller companies where earnings, balance ...

Altitude Lab, the platform-first biotech-startup accelerator founded by Recursion (NASDAQ: RXRX), announced today that its portfolio companies have collectively raised more ...

Big Pharma is pouring money into tech-devised treatments, but the verdict is out on whether they’ll actually work.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Celcuity , CAMP4 Therapeutics Corporation and Aquestive Therapeutics with bullish ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

A new frontier AI company called Recursive Superintelligence has emerged from stealth with $650 million in funding and an ...

The average one-year price target for Recursion Pharmaceuticals (NasdaqGS:RXRX) has been revised to $6.12 / share. This is a ...

Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis ...

Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) is one of the best AI stocks under $50 to buy right now. On May 6, Recursion reported significant progress across its AI-driven clinical pipeline for Q1 ...

Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid ...